XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Convertible Preferred Stock
 3 Months Ended
Mar. 31, 2022
Convertible preferred stock [Abstract]  
Convertible preferred stock
9. Convertible Preferred Stock
In connection with
 
the Reorganization, each
 
UNS convertible preferred share
 
was exchanged for
0.2191
 
shares of Vaxxinity
 
preferred
stock and
 
each share of
 
COVAXX
 
convertible preferred
 
stock was exchanged
 
for
3.4233
 
shares of Vaxxinity
 
preferred stock.
 
During
the first
 
and second
 
quarters of
 
2021, the
 
Company raised
 
gross proceeds
 
of $
122.8
 
million in
 
connection with
 
its Series
 
B preferred
stock financing. The
 
Company issued a total
 
of
15,365,574
 
shares at a price
 
of $
8.00
 
per share. All shares
 
of the Company’s
 
Series B
preferred stock converted
 
into shares
 
of the Company’s Class
 
A common stock
 
concurrently with
 
the closing
 
of the initial
 
public offering.
 
As of March 31, 2022 and
 
December 31, 2021, Vaxxinity’s
 
Amended and Restated Certificate
 
of Incorporation authorized
50,000,000
shares of
 
preferred stock
 
with a
 
par value
 
of $
0.0001
 
per share.
 
There were
 
no shares
 
of preferred
 
stock outstanding
 
as of
 
March 31,
2022 and December 31, 2021.